Recent Updates
Recently added Catalysts

Monad 1

Phase 2

Hemorrhoids | Small molecule | Other |Citius Pharmaceuticals, Inc.|Last Updated: Aug 31, 2023

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLEDBiomarker
Total Trials1
Total Enrollment304
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT05348200Safety and Efficacy of CITI-002 in Adult Patients With Moderate Grade HemorrhoidsPHASE2 COMPLETED 304Apr 22, 2022May 17, 2023Aug 31, 202316 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Change in Hemorrhoid symptoms
Day 8

Change in hemorrhoidal symptoms (pain, burning, itching, and swelling) as measured by the patient using a numeric rating scale.

Secondary Endpoints
Change in Hemorrhoidal bother.
Day 8
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Monad 1 creamACTIVE_COMPARATORTopical cream applied to the peri-anal area twice daily for seven days.
Monad 2 creamACTIVE_COMPARATORTopical cream applied to the peri-anal area twice daily for seven days.
Monad 3 creamACTIVE_COMPARATORTopical cream applied to the peri-anal area twice daily for seven days.
Combination-CITI-002 (low dose) creamEXPERIMENTALTopical cream applied to the peri-anal area twice daily for seven days.
Combination-CITI-002 (high dose) creamEXPERIMENTALTopical cream applied to the peri-anal area twice daily for seven days.
Interventions
NameTypeDescription
Monad 1DRUGSingle therapy cream containing Lidocaine. Lidocaine is a topical anesthetic.
Monad 2DRUGSingle therapy cream containing Halobetasol Propionate (low-strength). HPB is a topical corticosteroid.
Monad 3DRUGSingle therapy cream containing Halobetasol Propionate (high strength).
Combination - CITI-002 (low dose)DRUGCombination cream containing Lidocaine and HBP (low)
Combination - CITI-002 (high dose)DRUGCombination cream containing Lidocaine and HBP (high)
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites16

Inclusion Criteria: * Male or non-pregnant female 18 years of age or older. * Signs written informed consent for the study. * Females must be post-menopausal , surgically sterile , or use an effective method of birth control, or women of childbearing potential (WOCBP) must have a negative Urine Pre...

Countries:United States
Unlock Eligibility Criteria